Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Chinese Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone or Metformin in Combination With Sulfonylurea
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary) ; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 16 Mar 2020 Status changed from recruiting to discontinued.
- 11 Dec 2018 New trial record
- 03 Dec 2018 Status changed from not yet recruiting to recruiting.